Synthaverse

Synthaverse Current Assets

The Current Assets of Synthaverse (SVE.WA) as of Oct 20, 2026 is 99.15 M PLN. In the previous year, Current Assets was 45.36 M PLN — a change of 118.60% (higher).

Current Assets

99.15 MPLN

YoY

118.60%

Last updated:

Current Assets of Synthaverse is 2025 99.15 M PLN. Current Assets of Synthaverse was 2024 45.36 M PLN. It decreases by 118.60% higher compared to the previous year.

The Synthaverse Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
14.51 M PLN
Jan 1, 2019
15.13 M PLN
Jan 1, 2020
22.17 M PLN
Jan 1, 2021
40.82 M PLN
Jan 1, 2022
55.40 M PLN
Jan 1, 2023
51.99 M PLN
Jan 1, 2024
45.36 M PLN
Jan 1, 2025
99.15 M PLN
The Synthaverse Current Assets history
YEARCurrent AssetsYoY
99.15 MPLN+118.60%
45.36 MPLN-12.76%
51.99 MPLN-6.16%
55.40 MPLN+35.70%
40.82 MPLN+84.14%
22.17 MPLN+46.56%
15.13 MPLN+4.26%
14.51 MPLN-34.11%
22.02 MPLN-31.21%
32.01 MPLN-30.68%
46.18 MPLN-37.50%
73.89 MPLN+24.41%
59.39 MPLN+34.14%
44.27 MPLN+30.91%
33.82 MPLN+167.86%
12.63 MPLN-55.05%
28.09 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Synthaverse Stock analysis

What does Synthaverse do? Biomed Lublin is a Polish company that has been active in the production of serums and vaccines since 1950. It has grown to become a leading producer of biological substances and medical devices in Eastern Europe. The company was originally a state institution for the development of animal vaccines but was privatized after the political changes in the late 1980s. Since 2002, it has been listed on the Warsaw Stock Exchange and has expanded its focus. Biomed Lublin operates in four main areas: veterinary medicine, human medicine, diagnostics, and laboratory equipment. It has a strong reputation in the veterinary medicine field, offering vaccines and diagnostics for livestock and pets. The company is also involved in human medicine, producing vaccines and diagnostics exclusively in Poland. In the diagnostics field, Biomed Lublin has developed and manufactured a variety of test kits used in medical diagnostics. It also offers laboratory equipment such as microscopes, pipettes, and centrifuges for medical and biological testing in hospitals and laboratories. Overall, Biomed Lublin aims to continue expanding its presence in the biotech industry in Eastern Europe and providing high-quality and effective diagnostic and therapeutic solutions to improve the health of both humans and animals. Synthaverse is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Synthaverse stock

Current Assets of Synthaverse is 99.15 M PLN in 2025.

Current Assets of Synthaverse changed from 45.36 M PLN to 99.15 M PLN, representing a 118.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Synthaverse since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Synthaverse historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Synthaverse

All Key Metrics — Synthaverse